Special Issue

Design, Synthesis, and Evaluations of Antidepressant/Anticonvulsant/A Alzheimer Agents

Message from the Guest Editors

Neurologic disorders such as depression, convulsion. epilepsy, and Alzheimer's disease affect many people. In recent years, we have witnessed the discovery of numerous new organic compounds as potential antidepressant/anticonvulsant/anti-Alzheimer agents from de novo synthesis or structural modification of natural products. However, the development of new candidate drugs for the treatment of these diseases is still an urgent and intense need. Hence, so many scientists around the world are still involved in the discovery of new substances with antidepressant/anticonvulsant/anti-Alzheimer's disease activity. The aim of this Special Issue is to provide a platform for all scientists who are currently engaged in antidepressant/anticonvulsant/anti-Alzheimer drugs research. It is our great pleasure to invite you to contribute to this Special Issue and present your work in the form of communications, articles, or reviews

Guest Editors

Dr. Liping Guan

Food and Pharmacy College, Zhejiang Ocean University, Zhoushan 316022, China

Dr. Xianging Deng

Medical College, Jinggangshan University, Ji'an 343009, China

Deadline for manuscript submissions

closed (25 July 2023)



Molecules

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



mdpi.com/si/156451

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/molecules





Molecules

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 29th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

